Primers Archives — Page 3 of 3

Considering the Opportunity for a Differentiated Target Product Profile

Obesity physicians frame the opportunity for a non-GLP1 obesity therapeutic with the target product profile of a peripherally-inhibited CB1 inhibitor such as nimacimab.

Released June 20, 2025

Preclinical Models Highlight Utility of Peripheral CB1 Inhibition

Pharmacokinetic and pharmacodynamic models highlight the utility and sufficiency of peripherally-targeted versus central CB1 inhibition.

Released May 13, 2025

KOLs Discuss Potential of Non-GLP1 Mechanism for Metabolic Rewiring

New preclinical data highlight dose-dependent weight loss along with insights from KOLs regarding peripheral vs centrally-driven CB1 inhibition.

Released November 5, 2024

Obesity Specialists Weigh in on Need for New Anti-obesity Drugs

Skye and key opinion leaders offer insights into unmet treatment needs related to obesity, and the potential role of a next-generation CB1 inhibitor.

Released July 24, 2024